To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF

A Participant- and Investigator-blinded, Randomized, Placebo-controlled, Multicenter, Platform Study to Investigate Efficacy, Safety, and Tolerability of Various Single Treatments in Participants With Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov Identifier: NCT05497284

Novartis Reference Number: CADPT09A12201

Last Update: Nov 15, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis

Condition 
Idiopathic Pulmonary Fibrosis
Phase 
Phase 2
Overall status 
Recruiting
Start date 
Nov 10, 2022
Completion date 
Feb 03, 2025
Gender 
All
Age(s)
40 Years and older (Adult, Older Adult)

Interventions

Drug
LTP001
LTP001 will be administered once daily in the morning
Drug
Placebo
Placebo to LTP001 will be administered once daily in the morning
Drug
Standard of Care (SoC)
nintedanib, pirfenidone, or neither

Eligibility Criteria

Inclusion Criteria:

Male and female participants at least 40 years of age
IPF diagnosed based on ATS/ERS/JRS/ALAT IPF 2018 modified guidelines
FVC ≥45% predicted
DLCO, corrected for hemoglobin, ≥25% predicted (inclusive)
Unlikely to undergo lung transplantation during this trial in the opinion of the investigator
If a participant is taking nintedanib or pirfenidone, they must be on a stable regimen for at least 8 weeks prior to randomization

Exclusion Criteria:

Airway obstruction (i.e. prebronchodilator FEV1/ FVC < 0.7) or evidence of a bronchodilator response at screening
Emphysema >20% on screening HRCT
Fibrosis <10% on screening HRCT
Clinical diagnosis of any connective tissue disease
Clinically diagnosed acute exacerbation of IPF (AE-IPF) or other significant clinical worsening within 3 months of randomization

Additional protocol-defined inclusion / exclusion criteria may apply.

Study Locations

Australia
Novartis Investigative Site
Recruiting
Spearwood, 6163
Western Australia
Australia

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 
Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]